Eli Lilly and Company (NYSE:LLY) Receives Hold Rating from Berenberg Bank

Berenberg Bank reaffirmed their hold rating on shares of Eli Lilly and Company (NYSE:LLY) in a research report released on Wednesday, Marketbeat.com reports. Berenberg Bank currently has a $830.00 target price on the stock, down from their prior target price of $970.00.

LLY has been the subject of several other reports. HSBC upgraded shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and raised their price objective for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. JPMorgan Chase & Co. dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a research report on Sunday, August 17th. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $939.61.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $760.39 on Wednesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $939.86. The stock has a market cap of $719.68 billion, a P/E ratio of 49.70, a PEG ratio of 1.06 and a beta of 0.47. The company has a 50-day moving average price of $739.72 and a 200 day moving average price of $774.13. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company’s payout ratio is currently 39.22%.

Insider Buying and Selling

In other news, CEO David A. Ricks purchased 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.13% of the stock is currently owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently modified their holdings of the stock. Duquesne Family Office LLC lifted its position in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. Corient IA LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $570,000. LS Investment Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock worth $1,933,000 after buying an additional 40 shares during the last quarter. Cutter Capital Management LP purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $14,866,000. Finally, Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $207,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.